More than half of independent pharmacies are considering not stocking the first 10 drugs that were subject to Medicare price ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Good afternoon ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Total direct federal costs of covering AOMs would increase from $1.6 billion in 2026 to $7.1 billion in 2034, CBO finds.

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.

One of the biggest changes takes effect in 2025. Part D drug plans must cap out-of-pocket spending on covered drugs at $2,000 ...

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

The 2025 annual Medicare enrollment period runs from Oct. 15 to Dec. 7. Major changes are on the way for beneficiaries next ...

Medicare covers Wegovy as a treatment to reduce the risk of serious cardiovascular events in people who have overweight or obesity. It does not cover Wegovy for weight loss.